Company intelligence / Profile preview
Sangamo Therapeutics
Brisbane, California, United Statesen.wikipedia.org ↗
- Ownership
- Public · SGMO
- Employees
- ~354
- Development stage
- Phase 3
01
Overview
Sangamo is a pioneer in genomic medicine using proprietary zinc finger technology platforms. Its lead wholly owned programs target serious neurological and rare genetic diseases. The company has advanced its neurology pipeline toward the clinic and secured major licensing deals with Genentech and Astellas for novel capsid delivery technologies. The Fabry disease program is on an accelerated regulatory path after positive Phase I/II data; a pivotal BLA submission is anticipated in the second half of 2025. An IND was cleared for ST‑503 in iSFN pain with first patient dosing expected mid‑2025. Nonclinical proof-of-concept was demonstrated in prion disease models.[6][8]
- Therapeutic areas
- HematologyRare DiseasesNeurology
- Modalities
- Gene therapy (AAV-based gene transfer)Genome editing (Zinc Finger Nucleases - ZFN)Epigenetic regulation (Zinc Finger Protein Transcription Factors - ZFP-TF)
- Industry
- Biotech
02
Drug pipeline
32 assets31 more assets in the full pipeline.
Request access →03
Partnerships
Genentech/Roche – global epigenetic regulation & capsid delivery license agreement for neurodegenerative diseases[6]Astellas – capsid license agreement targeting up to five neurological indications[6]Previous or ongoing collaborations have included Pfizer, Biogen, Kite/Gilead, Lilly, Alexion, Takeda.[5][10]
04
Financials
- Market cap
- $30.7M
- Total revenue
- $1.4M
- Enterprise value
- $30.7M
Beyond the preview
Go deeper on Sangamo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sangamo Therapeutics.